Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
As Lisle looks to update brand, some question ‘Arboretum Village’ motto
As “The Arboretum Village,” Lisle has a tree logo displayed on its municipal campus and street... -
Milwaukee pair charged with identity theft in Round Lake
A pair of Milwaukee residents face five felony charges each stemming from an investigation into identity... -
Man dies in Aurora crash
A man died in a crash early Wednesday morning in Aurora.